Posted by Michael Wonder on 24 Jan 2024
Jardiance (empagliflozin) receives authorisation from Health Canada for the treatment of adults with chronic kidney disease
23 January 2024 - Health Canada has authorised Jardiance (empagliflozin) to reduce the risk of sustained eGFR decline, end stage kidney disease and cardiovascular and renal death in adults with chronic kidney disease, Boehringer Ingelheim (Canada) and Eli Lilly Canada announced today.
The authorisation has the potential to advance the standard of care for more than 4 million people in Canada living with chronic kidney disease.
